Susquehanna Fundamental Investments, LLC Adaptimmune Therapeutics PLC Transaction History

Susquehanna Fundamental Investments, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.5 - $5.68 $153,860 - $249,692	-43,960 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.44 - $6.37 $260,717 - $482,782	-75,790 Reduced 63.29%	43,960 $227,000
Q2 2021 Aug 11, 2021	SELL	$3.86 - $5.78 $154,168 - $230,853	-39,940 Reduced 25.01%	119,750 $510,000
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $59,094 - $82,369	-12,060 Reduced 7.02%	159,690 $848,000
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $273,660 - $629,418	68,415 Added 66.21%	171,750 $926,000

Q3 2020 Nov 16, 2020	BUY	$7.66 - $10.78 $299,774 - $421,875	39,135 Added 60.96%	103,335 $825,000
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $165,636 - $776,820	64,200 New	64,200 $643,000

160M

42.8K

42.1K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $191M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.